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Background. The increasing incidence of carbapenemase-producing 
Enterobacteriaceae (CPE) is a global health concern, as treatment options are 
extremely limited. The prevalence of CPE in UK hospitals is unknown, as national 
screening guidelines only recommend screening in patients considered to be at high-
risk of CPE. Patients in intensive care units (ICU) are at high-risk of healthcare-associ-
ated infections caused by multidrug-resistant organisms (MDRO).
Methods. We conducted a six-month prospective surveillance study to determine 
the prevalence of MDRO in a UK teaching hospital ICU. Between June and December 
2016, all adult patients admitted to ICU were screened for MDRO on admission, on 
discharge, and weekly during their ICU stay. Surveillance samples included stool or 
rectal swabs, urine, sputum or tracheal aspirates, and wound swabs (if wounds were 
present). Isolates were characterized phenotypically before undergoing whole-genome 
sequencing (WGS), epidemiological, and phylogenetic analyses.
Results. During the first week of the study we identified stool carriage of a mul-
tidrug-resistant Klebsiella pneumoniae strain in two patients neither of whom had rec-
ognized risk factors for CPE. Both isolates were resistant to all antibiotics tested, apart 
from colistin, and were PCR-positive for the blaNDM-1 gene. Enhanced surveillance by 
the infection control team identified four additional patients in several wards who had 
stool carriage (n = 3) or bloodstream infection (n = 1) with a blaNDM-1 K. pneumoniae 
isolate. Epidemiological links were identified between these six patients. Five months 
later, a second outbreak of multidrug-resistant K. pneumoniae was detected, involving 
stool carriage by four patients on two different wards. Environmental screening iden-
tified environmental contamination with multidrug-resistant K. pneumoniae on one 
ward. DNA sequence analysis confirmed that a novel blaNDM-1 K. pneumoniaelineage 
(ST78) was responsible for both outbreaks in the hospital.
Conclusion. We identified two unsuspected blaNDM-1 K. pneumoniae outbreaks in 
patients with no recognized risk factors for CPE. This highlights the importance of 
prospective surveillance for MDRO in high-risk settings, such as ICUs, and supports 
the use of rapid WGS to support outbreak investigations in real-time.
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Background. Carbapenem-resistant Enterobacteriaceae (CRE) and Acinetobacter 
baumannii (CRAB) pose a threat to public health, but comparisons of disease bur-
den are limited. We compared survival in patients following cultures positive for CRE 
or CRAB.
Methods. The Georgia Emerging Infections Program performs active popu-
lation-based and laboratory-based surveillance for CRE and CRAB in metropolitan 
Atlanta, GA. Using standard CDC definitions, we included patients who had incident 
carbapenem-nonsusceptible E. coli, Klebsiella spp., Enterobacter spp., or Acinetobacter 
baumannii isolated from urine only (noninvasive infection) or a sterile site (invasive 
infection) between 8/2011 and 12/2015. Death dates, verified by Georgia Vital Statistics 
records, were used to calculate 30- and 90-day mortality rates. We used the chi-square 
test for mortality rates and the log-rank test for survival analysis to 90 days to compare 
patients with invasive CRAB, noninvasive CRAB, invasive CRE, and noninvasive CRE.
Results. There were 535 patients with CRE (87 invasive, 448 noninvasive) and 
279 (78 invasive, 201 noninvasive) with CRAB. Nearly all patients with CRE and 
CRAB had healthcare exposures (97.2% vs. 100%) and most were immunosuppressed 
(62.6% vs. 56.3%). Both 30-day (24.4% vs. 18.3%, p  =  0.04) and 90-day (37.6% vs. 
30.5%, p  =  0.04) mortality were higher in patients with CRAB than CRE. Patients 
with invasive infections were more likely to die at 90 days than those with noninvasive 
infections (53.3% vs. 38.4%, p < 0.0001). Overall mortality rates for invasive infection 
were similar between CRAB and CRE at 30 (44.9% vs. 34.5% p  =  0.2) and 90  days 
(59.0% vs. 48.3%, p = 0.2). Using survival analysis at 90 days, invasive CRAB had the 
worst outcomes, followed by invasive CRE, noninvasive CRAB and noninvasive CRE 
(p < 0.0001, see Figure).
Conclusion. Ninety-day mortality for invasive infections with CRE and CRAB 
was ~50%, and patients with CRAB had lower survival than those with CRE, suggest-
ing that prevention efforts may need to prioritize CRAB as highly as CRE in facilities 
with endemic CRAB. With the high proportion of healthcare exposures and immu-
nosuppression, these infections may signify poor prognosis or directly contribute to 
mortality.
Disclosures. All authors: No reported disclosures.
1699. Prevalence and Acquisition of MRSA During Incarceration at a Large Inner-
city Jail
Kyle J Popovich, MD MS FIDSA1,2; Chad Zawitz, MD2; Alla Aroutcheva, MD, PhD1,2,; 
Darjai Payne, BS, MPH1; Michael Schoeny, PhD1; Emma Richardson, BS1; Mary 
K. Hayden, MD, FIDSA, FSHEA1; Bala Hota, MD, MPH1,2; Robert A. Weinstein, MD, 
FIDSA, FSHEA, FACP1,2; 1Rush University Medical Center, Chicago, Illinois; 2Stroger 
Hospital of Cook County, Chicago, Illinois 
Session: 190. Resist! MDROs in Healthcare 
Friday, October 6, 2017: 2:00 PM    
Background. USA300 MRSA is endemic in certain communities, with congre-
gate settings such as urban jails potentially facilitating spread. The extent of MRSA 
transmission in jail is unclear, a controversy that impacts prevention strategies. We 
determined the prevalence of MRSA colonization at jail entrance and defined the 
acquisition rate during incarceration.
Methods. Men incarcerated at the Cook County Jail, one of the largest US 
single-site jails, were enrolled within 72 hours of intake. Surveillance cultures 
(nares, throat, groin) were collected to determine prevalence of MRSA coloniza-
tion. A survey was administered to identify predictors of colonization. Detainees 
still in jail at Day30 had cultures repeated to determine MRSA acquisition rate. 
Univariate and multivariate analysis was performed to identify predictors of MRSA 
colonization.
Results. A total o 402 men (447 unique incarcerations) have so far been enrolled 
(77% AA, 11% Hispanic) with 92% previously in jail (20% in past 6  months). The 
prevalence of MRSA colonization at intake was 18.6% (83/447), with 39% of those 
colonized solely in the throat or groin. At 30 days: 10% (9/92) of initially negative men 
acquired MRSA; 14 admission positives remained colonized while 11 lost colonization. 
On univariate (Table), predictors of MRSA colonization at entrance to the jail were: 
methamphetamine use (METH), unstable housing, current skin infection, and care 
at an outpatient Clinic A that emphasizes comprehensive care to the LGBTQ commu-
nity. In this cohort, METH use was associated with reporting being a man who has sex 
with men vs. not (35% vs. 9%, P < 0.001) and was common among men with care at 
Clinic A (18% vs. 3%, P < 0.001). On multivariate with adjustment for race/ethnicity 
and HIV status, current skin infection and care at clinic A were associated with MRSA. 
Preliminarily, sharing personal items was associated with MRSA acquisition at Day30 
(OR = 5.6, 95% CI,1.3, 23.3, P = 0.02).
Conclusion. We found that a relatively high proportion of individuals enter the 
jail colonized with MRSA and the jail may amplify rates. Entrance colonization risk 
factors point to possible community reservoirs. Enrollment is ongoing but results sug-
gest an intervention in jail could impact MRSA rates in the jail and in the surrounding 
community.
